Publications by authors named "Anne Salz"
Article Synopsis
- High-grade non-muscle-invasive bladder cancer (HG NMIBC) patients have a high risk of progressing to muscle invasive cancer, and there is a need for new bladder-preserving treatments.
- Recent approvals of enfortumab vedotin, which targets NECTIN4, show potential for treating advanced bladder cancer, but more research is needed on NECTIN4 in HG NMIBC.
- A study found that NECTIN4 positivity was high (91% overall) in various HG NMIBC subgroups, with significant differences in expression levels, suggesting that NECTIN4-targeted therapies could be beneficial, particularly for patients with carcinoma in situ (CIS) and pure papillary tumors.
